Recent discussions on X about Mind Medicine (MindMed) stock, listed as MNMD, have been buzzing with interest following news of growing political momentum for psychedelic therapies. Many users are pointing to potential regulatory shifts, particularly with speculation around influential figures advocating for psychedelics in mental health treatment, as a key driver for the stock's recent surge. The excitement is palpable, with some predicting significant gains if legislative support materializes.
Conversations also highlight the company's progress in clinical trials, with several users expressing optimism about upcoming data readouts expected in the near future. While the tone is largely positive, there are cautious voices reminding others of the inherent risks in the biotech sector, especially with regulatory hurdles still looming. This blend of hope and caution keeps the dialogue dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
Mind Medicine (MindMed) Insider Trading Activity
Mind Medicine (MindMed) insiders have traded $MNMD stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MNMD stock by insiders over the last 6 months:
- ROBERT BARROW (Chief Executive Officer) has made 0 purchases and 2 sales selling 47,699 shares for an estimated $323,080.
- MARK SULLIVAN (Chief Legal Officer) has made 0 purchases and 2 sales selling 18,067 shares for an estimated $122,461.
- DANIEL KARLIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 14,684 shares for an estimated $99,441.
- CARRIE LIAO (Chief Accounting Officer) sold 2,347 shares for an estimated $15,818
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Mind Medicine (MindMed) Hedge Fund Activity
We have seen 81 institutional investors add shares of Mind Medicine (MindMed) stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCTAGON CAPITAL ADVISORS LP added 15,332,000 shares (+508.0%) to their portfolio in Q1 2025, for an estimated $89,692,200
- TRI LOCUM PARTNERS LP removed 820,793 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,801,639
- ROSALIND ADVISORS, INC. added 420,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,457,000
- BLACKROCK, INC. removed 354,340 shares (-5.8%) from their portfolio in Q1 2025, for an estimated $2,072,888
- DEEP TRACK CAPITAL, LP removed 316,594 shares (-11.2%) from their portfolio in Q1 2025, for an estimated $1,852,074
- CITADEL ADVISORS LLC added 291,630 shares (+239.5%) to their portfolio in Q1 2025, for an estimated $1,706,035
- COMMODORE CAPITAL LP added 216,575 shares (+5.0%) to their portfolio in Q1 2025, for an estimated $1,266,963
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Mind Medicine (MindMed) Analyst Ratings
Wall Street analysts have issued reports on $MNMD in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 05/09/2025
- Baird issued a "Outperform" rating on 03/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/07/2025
- Evercore ISI Group issued a "Outperform" rating on 01/28/2025
To track analyst ratings and price targets for Mind Medicine (MindMed), check out Quiver Quantitative's $MNMD forecast page.
Mind Medicine (MindMed) Price Targets
Multiple analysts have issued price targets for $MNMD recently. We have seen 4 analysts offer price targets for $MNMD in the last 6 months, with a median target of $21.5.
Here are some recent targets:
- Rudy Li from Chardan Capital set a target price of $20.0 on 05/09/2025
- Joel Beatty from Baird set a target price of $16.0 on 03/07/2025
- Patrick Trucchio from HC Wainwright & Co. set a target price of $55.0 on 03/07/2025
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $23.0 on 01/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
